Impact of Chronic Kidney Disease on Periprocedural Anticoagulation and Short-Term Outcomes after TAVR: A BRAVO-3 Trial Subanalysis
Victor Razuk(Mount Sinai Hospital), George Dangas(Mount Sinai Hospital), Davide Cao(Cardiovascular Institute of the South), Roberto Violini(IRCCS San Camillo Hospital), Samantha Sartori(Icahn School of Medicine at Mount Sinai), Aviv Alter(Elmhurst Hospital Center), Carlo Andrea Pivato(Cardiovascular Institute of the South), Roxana Mehran(Mount Sinai Hospital), Christophe Tron(Université de Rouen Normandie), Raban Jeger(Triemli Hospital), Sabato Sorrentino(Magna Graecia University), Alvin Mathew(Mount Sinai Health System), Nicolas Méneveau(Université de Franche-Comté), David Power(Cardiovascular Institute of the South), Prodromos Anthopoulos(Arena Pharmaceuticals (United States)), Davis Jones(Cardiovascular Institute of the South), Pieter R. Stella(University Medical Center Utrecht), Anton Camaj(Columbia University Irving Medical Center), Alessandro Spirito(University of Bern), Zhongjie Zhang(Shanxi Medical University), Nicolas Dumonteil(Clinique Pasteur), Johny Nicolas(Cardiovascular Institute of the South), Mauro Chiarito(Humanitas University), Frans Beerkens(Icahn School of Medicine at Mount Sinai), Markus Ferrari(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Julian D. Widder(Städtisches Klinikum Karlsruhe), Christian Hengstenberg(Medical University of Vienna)
Cited by 0
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k